Clinical trials
Terminated Phase 1 Myelodysplastic Syndromes trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
84 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 3 |
| 2006 | 3 |
| 2007 | 8 |
| 2008 | 6 |
| 2009 | 5 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 9 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 6 |
| 2021 | 6 |
| 2022 | 6 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 84 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Celgene | 4 |
| Masonic Cancer Center, University of Minnesota | 4 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 4 |
| Amgen | 3 |
| Boehringer Ingelheim | 2 |
| Bristol-Myers Squibb | 2 |
| Kyowa Kirin, Inc. | 2 |
| M.D. Anderson Cancer Center | 2 |
| National Cancer Institute (NCI) | 2 |
| Northwestern University | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myelodysplastic Syndromes | 84 |
| Leukemia, Myeloid, Acute | 56 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 24 |
| Leukemia | 21 |
| Leukemia, Myelomonocytic, Chronic | 18 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 17 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 15 |
| Lymphoma, Non-Hodgkin | 14 |
| Multiple Myeloma | 14 |
| Hodgkin Disease | 9 |
Trials
Showing 1 to 25 of 84. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.